Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
作者： Shun Lu
DOI: 10.2147/OTT.S188296
关键词:
摘要: Lung cancer is the leading cause of death in China, and approximately one third these cancers are squamous cell carcinoma (SqCC) lung. Ethnic diversity country-specific environmental factors can account for interindividual variations response to tolerability anticancer therapies. Although several targeted therapies have recently been approved patients with relapsed/refractory SqCC lung, only afatinib, an irreversible ErbB family blocker, has data Chinese patients. In Phase III LUX-Lung 8 trial, afatinib demonstrated a significant clinical benefit vs reversible first-generation EGFR tyrosine kinase inhibitor erlotinib both overall population subset, manageable safety profile. Emerging biomarker from suggest that mutations, especially ErbB2, those classified as "good" VeriStrat® proteomic test, may treatment particular, regardless ethnicity, get long-term response. conclusion, valid second-line option specific biomarkers help guide decision-making. Ongoing studies will provide further guidance on afatinib's place algorithm, alongside other novel
sci-hub.se 参考文章(80)
, A genomics-based classification of human lung tumors Science Translational Medicine. ,vol. 5, pp. 1- 28 ,(2013) , 10.1126/SCITRANSLMED.3006802
Qun‐Ying Hong, Guo-Ming Wu, Gui‐Sheng Qian, Cheng‐Ping Hu, Jian‐Ying Zhou, Liang‐An Chen, Wei‐Min Li, Shi‐Yue Li, Kai Wang, Qi Wang, Xiao‐Ju Zhang, Jing Li, Xin Gong, Chun‐Xue Bai, Lung Cancer Group of the Chinese Thoracic Society; Chinese Alliance Against Lung Cancer, None, Prevention and management of lung cancer in China Cancer. ,vol. 121, pp. 3080- 3088 ,(2015) , 10.1002/CNCR.29584
Michael A. Postow, Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 35, pp. 76- 83 ,(2015) , 10.14694/EDBOOK_AM.2015.35.76
Xiu-Yi Zhi, Jin-Ming Yu, Yuan-Kai Shi, Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer. ,vol. 121, pp. 3165- 3181 ,(2015) , 10.1002/CNCR.29550
Saravana M. Dhanasekaran, O Alejandro Balbin, Guoan Chen, Ernest Nadal, Shanker Kalyana-Sundaram, Jincheng Pan, Brendan Veeneman, Xuhong Cao, Rohit Malik, Pankaj Vats, Rui Wang, Stephanie Huang, Jinjie Zhong, Xiaojun Jing, Matthew Iyer, Yi-Mi Wu, Paul W. Harms, Jules Lin, Rishindra Reddy, Christine Brennan, Nallasivam Palanisamy, Andrew C. Chang, Anna Truini, Mauro Truini, Dan R. Robinson, David G. Beer, Arul M. Chinnaiyan, Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes Nature Communications. ,vol. 5, pp. 5893- 5893 ,(2014) , 10.1038/NCOMMS6893
Jean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, Lisa F Licitra, Makoto Tahara, Jan B Vermorken, Paul M Clement, Thomas Gauler, Didier Cupissol, Juan José Grau, Joël Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M del Campo, Xiuyu Julie Cong, Eva Ehrnrooth, Ezra E W Cohen, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial The Lancet Oncology. ,vol. 16, pp. 583- 594 ,(2015) , 10.1016/S1470-2045(15)70124-5
Jean-Louis Pujol, Robert Pirker, Thomas J. Lynch, Charles A. Butts, Rafael Rosell, Frances A. Shepherd, Johan Vansteenkiste, Kenneth J. O’Byrne, Barbara de Blas, Jim Heighway, Anja von Heydebreck, Nick Thatcher, Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer Lung Cancer. ,vol. 83, pp. 211- 218 ,(2014) , 10.1016/J.LUNGCAN.2013.11.006
Nagahiro Saijo, The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Medical Journal. ,vol. 54, pp. 1- 14 ,(2013) , 10.3349/YMJ.2013.54.1.1
Thomas E. Stinchcombe, Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Medical Oncology. ,vol. 31, pp. 960- 960 ,(2014) , 10.1007/S12032-014-0960-1
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts, Adam Kiezun, Peter S Hammerman, Aaron McKenna, Yotam Drier, Lihua Zou, Alex H Ramos, Trevor J Pugh, Nicolas Stransky, Elena Helman, Jaegil Kim, Carrie Sougnez, Lauren Ambrogio, Elizabeth Nickerson, Erica Shefler, Maria L Cortés, Daniel Auclair, Gordon Saksena, Douglas Voet, Michael Noble, Daniel DiCara, Pei Lin, Lee Lichtenstein, David I Heiman, Timothy Fennell, Marcin Imielinski, Bryan Hernandez, Eran Hodis, Sylvan Baca, Austin M Dulak, Jens Lohr, Dan-Avi Landau, Catherine J Wu, Jorge Melendez-Zajgla, Alfredo Hidalgo-Miranda, Amnon Koren, Steven A McCarroll, Jaume Mora, Ryan S Lee, Brian Crompton, Robert Onofrio, Melissa Parkin, Wendy Winckler, Kristin Ardlie, Stacey B Gabriel, Charles WM Roberts, Jaclyn A Biegel, Kimberly Stegmaier, Adam J Bass, Levi A Garraway, Matthew Meyerson, Todd R Golub, Dmitry A Gordenin, Shamil Sunyaev, Eric S Lander, Gad Getz, None, Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature. ,vol. 499, pp. 214- 218 ,(2013) , 10.1038/NATURE12213